Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the ...
21 Juin 2021 - 2:01PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
presented new epidemiology data on migraine from the State of
Israel which indicate that socio-economic factors may contribute to
underdiagnosis of migraine across society1.
A retrospective study of migraine epidemiology in Southern
Israel, supported by Teva and presented at the virtual 7th Congress
of the European Academy of Neurology (EAN), found extreme
variability in the prevalence of diagnosed patients with migraine
across the geographic area studied.
Prevalence rates were positively associated with the
socio-economic status of the geographic area studied, suggesting
that those living with migraine from less advantaged areas may find
it harder to achieve an accurate diagnosis and thereby access
appropriate therapy.
“These findings are concerning not least because they suggest
significant ‘migraine awareness inequity’ in this population,” said
Professor Gal Ifergane, study investigator, practitioner, head of
the Department of Neurology and chair of the Division of Brain
Medicine at Soroka University Medical Center, Ben-Gurion University
of the Negev, Beer-Sheva, Israel.
“While our study focuses on one region of one country, it may
indicate this type of inequity is common in other parts of the
world. Migraine is a difficult, challenging neurological disease
which does not discriminate dependent on an individual’s social
status. We conclude that underdiagnosis could be as much a social
problem as a medical problem, and this requires further
consideration if we are to ensure all those who live with migraine
have access to the therapeutic interventions which are right for
them. We believe migraine should be prioritised as a highly
prevalent and often under-looked neurological disorder.”
The study findings build on an increasingly clear understanding
of the challenges facing people living with migraine. A 2020
Teva-sponsored research project, Beyond Migraine: The Real You,
surveyed over 7,500 people living with the disease in 10 European
countries. It discovered that people living with migraine struggled
to support themselves or advocate for improved disease management.
The survey exposed the often-devastating impact of migraine on all
aspects of a patient's life, across personal relationships, work
life, social life and education.
- 60% of people living with migraine indicated that the disease
had negatively impacted their social life, studies, work and
career
- 40% of young people living with migraine indicated a negative
impact on their education
- Only 1 out of 8 individuals belonged to a patient support
group
“We were pleased to support these research efforts, which throw
into sharp relief the social inequality which is clearly prevalent
in migraine,” said Dr Joshua M. Cohen, Senior Director and Global
Therapeutic Area Lead, Migraine and Headache, Teva.
“Our commitment as Teva is to support improvements in migraine
holistically, working with the neurology community and allied
professionals to advance not only effective therapies, but better
diagnosis, information and conditions for all those who live with
this debilitating disease. We look forward to continuing our
extensive research commitment as a partner to all those impacted by
migraine, regardless of their location or social situation.”
About the Epidemiological Study
A total of 29,938 migraine patients were identified from of
391,528 adult public health records. The overall prevalence (per
10,000 adults) of migraine was 764.64 (7.64%), 1143.34 (11.43%) for
women and 374.97 (3.74%) for men. Among the area studied, adjusted
prevalence ranged from 386.14 (3.86%) to 1320.59 (13.20%). The
female-to-male ratio ranged from 1.18:1 to 5.1:1.
About the ‘Beyond Migraine: The Real You survey
- The digital survey was conducted as part of the 'Beyond
Migraine; The Real You' Campaign in 10 countries (Belgium, Czech
Republic, France, Germany, Italy, Netherlands, Poland, Spain,
Sweden and the UK) between November 2019-December 20192.
- All respondents were 18+ years old and experienced migraine
attacks for at least 4 days a month (self-reported).
- The total sample size was 7,520.
Accessing EAN 2021 Presentations
The ePresentations shared by Teva at EAN 2021 can be accessed by
healthcare professionals via the EAN conference website, and
available on-demand for EAN members.
Additional resources on migraine, including articles,
publication summaries, podcasts and webinars can be accessed at
Neurologybytes. Neurologybytes is a platform published by Teva to
support neurologists in accessing timely, bite-sized content on the
latest research developments and clinical care perspectives in the
world of migraine and multiple sclerosis (MS).
Information for Europe about AJOVY® from the European Medicines
Agency (EMA) can be found here.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to:
- our ability to successfully compete in the marketplace,
including: that we are substantially dependent on our generic
products; consolidation of our customer base and commercial
alliances among our customers; delays in launches of new generic
products; the increase in the number of competitors targeting
generic opportunities and seeking U.S. market exclusivity for
generic versions of significant products; our ability to develop
and commercialize biopharmaceutical products; competition for our
specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our
ability to achieve expected results from investments in our product
pipeline; our ability to develop and commercialize additional
pharmaceutical products; and the effectiveness of our patents and
other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to
incur additional indebtedness, engage in additional transactions or
make new investments, may result in a further downgrade of our
credit ratings; and our inability to raise debt or borrow funds in
amounts or on terms that are favorable to us;
- our business and operations in general, including: uncertainty
regarding the COVID-19 pandemic and its impact on our business,
financial condition, operations, cash flows, and liquidity and on
the economy in general; our ability to successfully execute and
maintain the activities and efforts related to the measures we have
taken or may take in response to the COVID-19 pandemic and
associated costs therewith; effectiveness of our optimization
efforts; our ability to attract, hire and retain highly skilled
personnel; manufacturing or quality control problems; interruptions
in our supply chain; disruptions of information technology systems;
breaches of our data security; variations in intellectual property
laws; challenges associated with conducting business globally,
including political or economic instability, major hostilities or
terrorism; costs and delays resulting from the extensive
pharmaceutical regulation to which we are subject or delays in
governmental processing time due to travel and work restrictions
caused by the COVID-19 pandemic;
- the effects of reforms in healthcare regulation and reductions
in pharmaceutical pricing, reimbursement and coverage; significant
sales to a limited number of customers; our ability to successfully
bid for suitable acquisition targets or licensing opportunities, or
to consummate and integrate acquisitions; and our prospects and
opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including:
failure to comply with complex legal and regulatory environments;
increased legal and regulatory action in connection with public
concern over the abuse of opioid medications and our ability to
reach a final resolution of the remaining opioid-related
litigation; scrutiny from competition and pricing authorities
around the world, including our ability to successfully defend
against the U.S. Department of Justice criminal charges of Sherman
Act violations; potential liability for patent infringement;
product liability claims; failure to comply with complex Medicare
and Medicaid reporting and payment obligations; compliance with
anti-corruption sanctions and trade control laws; and environmental
risks;
- other financial and economic risks, including: our exposure to
currency fluctuations and restrictions as well as credit risks;
potential impairments of our intangible assets; potential
significant increases in tax liabilities (including as a result of
potential tax reform in the United States); and the effect on our
overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our
business; and other factors discussed in this press release, in our
Quarterly Report on Form 10-Q for the first quarter of 2021 and in
our Annual Report on Form 10-K for the year ended December 31,
2020, including in the sections captioned "Risk Factors” and
“Forward Looking Statements.” Forward-looking statements speak only
as of the date on which they are made, and we assume no obligation
to update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
References
- Ifergane et al, 2021. A retrospective database study of
migraine epidemiology in Southern Israel. Presented at EAN 2021, 21
June 2021.
- Beyond Migraine: The Real You. A survey commissioned by Teva,
2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210621005186/en/
PR Contacts Fiona Cohen, Teva Europe
Fiona.Cohen@TevaEU.com +31 6 20 08 25 45
Con Franklin, Ketchum con.franklin@ketchum.com +44 (0) 7974 434
151
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024